US equities |
MU $1,070.79 ▲+2.41% NVDA $237.19 ▼-0.86% SNDK $1,707.57 ▲+2.84% AMD $642.93 ▼-1.00% INTC $113.61 ▲+0.98% SPCX $168.57 ▼-1.95% TSLA $375.36 ▼-1.40% AAPL $335.20 ▲+0.47%
FinancialContent

Latest News about Jason Gerberry

Recent news which mentions Jason Gerberry

Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says
Tickers XENE
Tags Jason Gerberry XENE BofA Securities
From Benzinga
Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate'
Tickers TEVA
Tags Price Target Jason Gerberry BofA Securities
From Benzinga
Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical
Tickers AXSM
Tags Analyst Color Benzinga News
From Benzinga
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal
Tickers TEVA
Tags Analyst Color General Analyst Ratings
From Benzinga
BofA Initiates Arcellx With Buy On Its Novel Therapy Approach
Tickers ACLX
Tags BofA Securities Analyst Ratings Jason Gerberry
From Benzinga
BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?
Tickers IONS
Tags Benzinga Biotech Market News
From Benzinga
BofA Downgrades Alkermes After Stock Rally: 'We Don't See A Favorable Catalyst Pathway'
Tickers ALKS
Tags Analyst Color Benzinga General
From Benzinga
FibroGen Analyst Removes Roxadustat Sales From Model After AdCom Snub
Tickers FGEN
Tags Downgrades Trading Ideas Movers
From Benzinga